Thus, targeting pathways that sustain MYC activity, particularly in the context of MEK inhibition, presents a promising therapeutic strategy to exploit this addiction and enhance treatment efficacy in HNSCC. The gene discussed is MAP2K7; the disease is head and neck squamous cell carcinoma.